To address this issue, we examined the development of the ENS in mice engineered to express RET C618F, one of the MTC-associated RET-activating mutants, under the endogenous Ret promoter (Okamoto et al., 2019). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.